Asset profile
AZD5462
Small molecule
Evidence outlook · results not reported
LUMINARA (NCT06299826) · Chronic Heart Failure
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
LUMINARA (NCT06299826): The study was randomized, double-blind, and placebo-controlled, with 375 participants across three AZD5462 dose groups and a placebo group. Its primary endpoint was a surrogate echocardiographic measure, and no primary-outcome results or statistical comparison are currently available.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 2 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD5462: this drug | Phase 2 | Small molecule | Relaxin receptor (RXFP1) / relaxin | ||
| AZD3427 | Phase 2 | Peptide | Relaxin receptor (RXFP1) / relaxin | ||
| R2R01 | Phase 2 | Peptide | Relaxin receptor (RXFP1) / relaxin | ||
| Fc-Relaxin Fusion Protein (TX45) | Phase 2 | Protein / enzyme therapeutic | Relaxin receptor (RXFP1) / relaxin | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | ||
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | ||
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Approved | Device Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | ||
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) | ||
| Ivabradine (Corlanor) | Approved | Small molecule | If (funny) channel | ||
| Mavacamten (Camzyos) | Approved | Small molecule | Cardiac myosin (inhibitor) |
…and 48 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.